



iCo Therapeutics Inc (TSX-V: 'ICO')

760-777 Hornby St.
Vancouver, BC
V6Z 1S4 Canada

Tel: 604-602-9414
Fax: 604-602-9699
www.icotherapeutics.com

iCo-007 targets Diabetic Macular Edema (DME), the leading cause of blindness in working age adults.

There are no FDA-approved therapeutics for Diabetic Macular Edema.

iCo-007 is a 'Green Field' Opportunity

- There are currently **no approved therapeutics** on the market for DME
- DME's **underlying cause is Diabetes** - a massive and growing problem
- Currently, **1.6M DME patients** in the US alone – a number that is expected to grow as Diabetes is set **to increase by almost 50%** in the US by 2025
- Assuming a conservative 20% penetration at a 60% discount to comparable retinal treatments, iCo-007 has a potential market of **\$3 Billion**
- Large pharma have **limited ocular pipelines** - large acquisition & partnership deals in the ocular space create possibility for earlier stage, attractive exit strategies

What are iCo-007's advantages?

- iCo licensed the **exclusive world-wide rights** to iCo-007 from ISIS Pharmaceuticals
- ISIS is iCo's largest shareholder, having taken milestone payments in equity at a **premium to current market**, remainder of milestones heavily back-end loaded.
- ISIS recently signed a deal with **Genzyme for \$1.9B** – an important validation of iCo -007's underlying technology (2nd generation antisense)
- iCo's 'reprofiling' approach took iCo-007 into the clinic at **1/15th of the cost** and in far **less time** compared to traditional development
- iCo-007 targets **multiple growth factors** including VEGF & has a **longer half-life**, making it attractive to ophthalmologists (can see more patients due to less frequent injections & potentially more effective treatment)

What is iCo-007's clinical plan?

- iCo-007 is currently in a **Phase I clinical trial** – importantly, this trial will be **undertaken in DME patients as opposed to healthy volunteers**, giving iCo the opportunity to see hints of efficacy far in advance of a Phase II trial
- Primary endpoint is safety, but secondary endpoints include visual acuity & retinal thickness – measures that are of great interest to big pharma

H1 2008: Phase I underway; ongoing partnership discussions; presentations at influential international conferences

H2 2008: Interim safety results **H1 2009:** Final results & Phase II initiation

Contact: Frederica Bell bell@icotherapeutics.com (o) 604-602-9414 (c) 778-385-2549